0
Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review.
Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.
Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment.
Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report.
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Complete response of squamous cell carcinoma of the lung following treatment with pembrolizumab in an elderly patient: A case report.
Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
First line Immunotherapy for Non-Small Cell Lung Cancer.
PD-L1 vs. Tumor mutation burden, which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS® Registry.
Institutional financial toxicity of failure to adhere to treatment guidelines for head and neck squamous cell carcinoma.
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma.
Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab.
Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer.
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study.
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Localized muscle spasm as a manifestation of pembrolizumab-induced infusion reaction.
Tumoral melanosis after immunotherapy with pembrolizumab - a response sign mimicking melanoma.
Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports.
Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.
Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab.
Biomarkers in immunotherapy: literature review and future directions.
Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update.
A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041).
Infectious complications in patients treated with immune checkpoint inhibitors.
Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.
Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade.
Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy.
Programmed Death-1 Inhibitors-induced Bullous Pemphigoid in 21 Cases.
A Case of Recurrent Thymoma Treated with Pembrolizumab as the Fifth-Line Chemotherapy.
Clinical Efficacy of Monotherapy with Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer.
A Case of Advanced Gastric Cancer of an Elderly Patient Responding Effectively to Pembrolizumab.
Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report.
Immune checkpoint inhibition in upper tract urothelial carcinoma.
The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma.
Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.
Pembrolizumab Induced Hypophysitis in a Patient Allergic to Triamcinolone: An Increasingly Recognized Endocrinopathy Related to Immunotherapy.
Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report.
Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy.
A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Immunotherapy in prostate cancer: new horizon of hurdles and hopes.
Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab.
The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Monitoring real-life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry.
Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells.
Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.
Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database.
Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis.
Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience.
Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.
A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.
Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis.
Disease Response to Pazopanib in Follicular Dendritic Cell Sarcoma.
Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein.
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report.
Early 3+3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors.
Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma.
Primary Melanoma of the Lacrimal Sac Treated With Pembrolizumab.
A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
Finding the hot spot: identifying immune sensitive gastrointestinal tumors.
Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report.
18FFluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
"Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced ""Eosinophilic Fasciitis-Like"" Case and a Review of the Literature."
Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up.
Immunoherapy Treatment Against Cervical Cancer.
Metastatic Merkel Cell Carcinoma Masquerading as Multiple Immune-Related Adverse Events.
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.
Thyroid disorders associated with immune control point inhibitors.
Immune checkpoint inhibitors for treatment of advanced stage melanoma.
Targeted therapy for metastatic renal cell carcinoma.
Extensive bilateral renal metastases of non-small cell lung carcinoma caused acute kidney injury resulting in end-stage renal disease.
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions.
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
Programmed cell death protein 1 inhibitor-induced recalcitrant mixed small and medium vessel vasculitis.
A concise review of the changing landscape of hepatocellular carcinoma.
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
Immunotherapy in gastroesophageal cancers: Current state and future directions.
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
The Immunotherapy Landscape in Renal Cell Carcinoma.
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
Interstitial nephritis with pembrolizumab: A case report and review.
Regulation of NFκB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?
Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.
Durable Response in a Case of Metastatic Anaplastic Thyroid Cancer Using a Combination of Tyrosine Kinase Inhibitors and a Check Point Inhibitor.
Advances in targeted therapy for esophageal cancer.
Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial.
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature.
Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report.
Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy.
Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumours.
Management of the Adverse Effects of Immune Checkpoint Inhibitors.
Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Pembrolizumab and atezolizumab in triple-negative breast cancer.
Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade.
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.
Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and &#39;0-7-21&#39; Radiotherapy Regimen (24 Gy/3 fractions/21 days).
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Kidney Cancer: An Overview of Current Therapeutic Approaches.
Immunotherapy for advanced hepatocellular carcinoma, where are we?
The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Pembrolizumab for the treatment of Hodgkin Lymphoma.
Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab.
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Pancreatitis and Biliary Obstruction Secondary to Duodenal Metastasis from Rapidly Progressing Lung Adenocarcinoma Treated with Common Bile Duct Stenting.
Designing novel immunocombinations in metastatic renal cell carcinoma.
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
Systematic review of neoadjuvant therapy by Immune checkpoint inhibitors before radical cystectomy: where do we stand?
Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Cuation Advised Using Combination Ketoconazole and PD-1 Inhibitors.
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation.
Long-Lasting Response after Pembrolizumab in a Patient with Metastatic Triple-Negative Breast Cancer.
Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone.
Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.
Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab.
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
The application of target-based tissue-agnostic therapy in the treatment of lung cancer.
Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors.
Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research.
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma.
Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus.
Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.
Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report.
Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Systemic thromboembolism from a misdiagnosed non-bacterial thrombotic endocarditis in a patient with lung cancer: A case report.
What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
"Advances in urologic oncology ""OncoForum"": The best of 2019."
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
All in the Levels-Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer.
Pembrolizumab on pre-existing inclusion body myositis: a case report.
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.
Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature.
Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.
Medication-Specific Variations in Morphological Patterns of Injury in Immune Checkpoint Inhibitor-Associated Colitis.
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report.
Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis.
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Checkpoint inhibitors-indications and application in melanoma patients.
Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients.
Immune-Mediated Toxic Epidermal Necrolysis.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus.
Progressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: An autopsy case report.
"""Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma""."
Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab.
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pembrolizumab Exacerbates Thyroid Diseases Shown on FDG PET/CT.
Complete clinical response of a neglected cutaneous melanoma with combined radiotherapy and immunotherapy: A case report.
Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review.
Advances in antibody therapy for B cell lymphoma.
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma.
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Immunotherapy in Small Cell Lung Cancer.
Current and emerging treatment options for metastatic melanoma: a focused review.
An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma.
Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report.
Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre.
Dermatological side effects rarely interfere with the continuation of checkpoint inhibitor immunotherapy for cancer.
Cervical cancer in pregnancy.
Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors.
Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.
Current Microsatellite Instability Testing in Management of Colorectal Cancer.
Pembrolizumab-Induced Cold Agglutinin Disease.
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
Targeting angiogenesis for liver cancer: Past, present, and future.
Pembrolizumab-induced Myositis in the Setting of Metastatic Melanoma: An Increasingly Common Phenomenon.
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma.
Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.
Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy.
Pembrolizumab-induced Radiation Recall Pneumonitis After the Resolution of Typical Asymptomatic Radiation Pneumonitis.
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.
Management of brain metastases according to molecular subtypes.
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer.
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges.
Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching.
Pembrolizumab-Induced Sarcoid-Like Reaction: FDG-PET Scan Interpretation in the Era of Immunotherapy.
Primary Gastric Adenosquamous Carcinoma: A Case Report.
Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Gastric cancer.
Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives.
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report and literature review.
Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality.
Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience.
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma.
Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study.
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.
An update on the immune landscape in lung and head and neck cancers.
IL-32γ potentiates tumor immunity in melanoma.
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins.
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism.
Discovery of Potent and Orally Available Bicyclo1.1.1pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors.
Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma.
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Risk Factors for Anti-PD1 Antibody-Induced Skin Eruptions.
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas.
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.
Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition.
Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma.
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma.
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.
Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
Safety of pembrolizumab for resected stage III melanoma.
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review.
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting.
Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Immuno-oncology for esophageal cancer.
Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Immunotherapy for squamous cell carcinoma of the head and neck.
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.
Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Real-world treatment practice in patients with advanced melanoma.
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Successful use of a therapeutic trial of graduated volume and dose escalation for postoperative head and neck radiotherapy in a Fanconi anemia patient.
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey.
Complete remission in a patient with advanced renal pelvis carcinoma with lung metastasis treated with durvalumab immunotherapy: a case report.
Complete response to pembrolizumab in a patient with extensive-stage small-cell lung cancer: a case report.
Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable or metastatic melanoma with BRAF V600 mutation: A systematic review and network meta-analysis.
Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis.
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab.
Metastatic Pancreatic Cancer: ASCO Guideline Update.
Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies.
Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report.
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC.
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Systemic treatment options for advanced biliary tract carcinoma.
Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report.
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management.
Immune checkpoint inhibitor-induced musculoskeletal manifestations.
Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.
Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors.
Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer.
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report.
Atypical Takotsubo Cardiomyopathy Secondary to Combination of Chemo-Immunotherapy in a Patient With Non-Small Cell Lung Cancer.
Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine.
Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story.
Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives.
Advances in immunotherapy for cervical cancer.
Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report.
Neoadjuvant chemotherapy before radical cystectomy: why we must adhere?
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China.
Rapid onset type 1 diabetes with anti-PD-1 directed therapy.
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Novel treatments for progressive multifocal leukoencephalopathy.
Immunotherapy - new perspective in lung cancer.
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
18FFDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Targeted Therapies in Advanced Gastric Cancer.
Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass.
A Study on the Number of Cycles of First-Line Chemotherapy for Advanced Urothelial Carcinoma.
Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Author Correction: NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Adjuvant Therapy for Melanoma: Past, Current, and Future Developments.
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke.
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature.
A Review of Immune-Mediated Adverse Events in Melanoma.
Seizure as the first manifestation of transitional cell carcinoma of the renal pelvis.
Applied precision medicine in metastatic pancreatic ductal adenocarcinoma.
Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer.
Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma.
Epidemiology, Staging and Management of Prostate Cancer.
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179.
Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy.
Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial).
Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia.
Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report.
ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab.
Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
Pembrolizumab-Induced Ocular Myasthenic Crisis.
Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.
Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer.
Targeting defective DNA repair in prostate cancer.
Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
A Common Pituitary Autoantibody In Two Patients With Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8.
Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report.
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Current concepts and approaches to merkel cell carcinoma.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas.
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report.
Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Antiemetics: ASCO Guideline Update.
Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis.
Severe oral erosive lichenoid reaction to pembrolizumab therapy.
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report.
Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
Immunotherapy in Anal Cancer.
Therapy preferences in melanoma treatment-Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease.
FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome.
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
Oncology Nurse Coordinators in Clinical Trials - Shaking up the Melanoma Team.
Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors.
Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy.
Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists.
Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report.
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.
Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC.
Pembrolizumab for the treatment of esophageal cancer.
Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.
Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.
Anti-PD-1 Therapy-Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma.
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach.
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report.
Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma.
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date.
Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors.
Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer.
Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review.
Tumor Volume Dynamics as an Early Biomarker for Patient-Specific Evolution of Resistance and Progression in Recurrent High-Grade Glioma.
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.
The Role of Neoadjuvant Therapy in Melanoma.
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Sequencing Therapies for Metastatic Renal Cell Carcinoma.
Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
Allergic Fungal Sinusitis Imitating an Aggressive Skull Base Lesion in the Setting of Pembrolizumab Immunotherapy.
Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study.
Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series.
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.
Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Use of checkpoint inhibitors in gray zone lymphoma.
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Antibody-drug conjugates for the treatment of urothelial carcinoma.
Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy.
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities.
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study.
Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.
The emerging role of antibody-drug conjugates in urothelial carcinoma.
Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer.
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy.
The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report.
Neoadjuvant therapy for muscle-invasive bladder cancer.
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.
Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab.
Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients.
Risk of scleroderma according to the type of immune checkpoint inhibitors.
A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
Advances in immunotherapy for colorectal cancer: a review.
Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management.
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells.
Histology-agnostic drug development - considering issues beyond the tissue.
Hepatocellular carcinoma, novel therapies on the horizon.
A Case of Acquired Generalized Lipodystrophy Assocaited with Pembrolizumabin a  Patient with Metastatic Malignant Melanoma.
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
Associated Myocarditis: A Predictive Factor for Response?
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma.
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma.
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection.
HK3 is correlated with immune infiltrates and predicts response to immunotherapy in non-small cell lung cancer.
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Advanced papillary thyroid carcinoma responding to nivolumab.
Immune checkpoint inhibitor therapy for cancer patients infected with HIV: A systematic review.
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology.
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report.
Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab.
What is new in the diagnosis and therapy of renal cell carcinoma?
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis.
A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy.
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.
Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
PD-1 Inhibitor Bests Chemo for Colorectal Cancer.
A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology.
Pembrolizumab May Enhance Current Treatments for Esophagogastric Cancers.
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Current status of immune checkpoint inhibitors for gastric cancer.
Histologic patterns of liver injury induced by anti-PD-1 therapy.
CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
Genetics of HCC: Novel approaches to explore molecular diversity.
Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
Immune checkpoint inhibitors in lung cancer.
Immune checkpoint inhibitors to treat cutaneous malignancies.
Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study.
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report.
An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient.
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Bilateral Corneal Graft Rejection Associated With Pembrolizumab Treatment.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
Sequential systemic treatment in patients with hepatocellular carcinoma.
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab.
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Advanced melanoma in adults: Pembrolizumab as a treatment option.
Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer.
Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer.
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.
Acral vascular syndrome during an immune checkpoint inhibitor.
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Prognostic and predictive role of the tumor immune landscape.
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report.
Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab.
Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation.
Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
Toripalimab for the treatment of melanoma.
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Nanoengineered targeting strategy for cancer immunotherapy.
Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation.
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab.
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.
Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma.
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.
Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin.
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
Immune checkpoint inhibitors (ICIs)-related ocular myositis.
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Myasthenia Gravis and Myositis(PD-1 Myopathy).
Pulmonary Adenocarcinoma Responding to Fourth-Line S-1 Monotherapy-A Case Report.
Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.
A case of impaired consciousness due to large cystic metastatic brain tumors from lung adenocarcinoma successfully controlled with Ommaya reservoir placement.
Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication.
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
Immunotherapy in hematologic malignancies.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin's Lymphoma.
Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy.
Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration.
Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.
Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study.
Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma.
Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature.
A Rare Case of Autoimmune Demyelinating Polyneuropathy and Hydrocephalus Secondary to Pembrolizumab.
Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Major clinical research advances in gynecologic cancer in 2019.
PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.
Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Central nervous system complications associated with immune checkpoint inhibitors.
A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab.
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date.
Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report.
Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis.
Tumor-Agnostic Treatment for Cancer: When How is Better than Where.
Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis.
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC.
Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge.
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.
First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
Immune-Related Oral, Otologic, and Ocular Adverse Events.
Immunotherapy in Lung Cancer: From a Minor God to the Olympus.
Immunotherapy for Melanoma.
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature.
Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.
Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer.
Bilateral Poorly Differentiated Adenocarcinoma of the Lacrimal Gland With Tumor Regression After Treatment With Pembrolizumab.
Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening.
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab.
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.
Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer.
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Oesophagobronchial perforations after placement of an oesophageal self-expanding metallic stent.
The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study.
Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?
Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma.
Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.
An analysis of early morning acth levels in the first case of pembrolizumab-induced adrenalitis as a delayed immune-related event (dire) - case study.
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Positron-emission tomography-guided radiation therapy: Ongoing projects and future hopes.
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report.
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Bilateral Serous Retinal Detachment and Uveitis Associated with Pembrolizumab Treatment in Metastatic Melanoma.
"Cancer Immunoprevention: A Case Report Raising the Possibility of ""Immuno-interception""."
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
Transient acantholytic dermatosis in a patient with prostate cancer.
Bullous pemphigoid induced by cancer immunotherapy.
Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer.
Carcinoma in situ of the bladder: why is it underdetected?
Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model.
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.
Systemic Therapy for Melanoma: ASCO Guideline.
Metastatic melanoma presenting as intravenous tumour thrombus.
Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes.
Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay.
Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.
Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer.
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Antibody characterization using immunosignatures.
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
IDO Targeting in Sarcoma: Biological and Clinical Implications.
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report.
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
Discovery of New Immune Checkpoints: Family Grows Up.
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer.
Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer-A matched case-control study.
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer.
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction.
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival.
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs.
Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Microsatellite Instability in Gastric Cancer.
A Case of Bladder Urothelial Carcinoma with Hepatic Metastasis Achieving Histologically Complete Response by Multimodal Treatment Including Pembrolizumab.
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
Immunotherapy in Malignant Pleural Mesothelioma.
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy.
Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma-A Single Institutional Experience and Literature Review.
Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy.
Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature.
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting.
Primary pulmonary lymphoepithelioma-like carcinoma.
Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Central Nervous System-Invading Eccrine Gland Carcinoma: A Clinicopathologic Case Series and Literature Review.
Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.
Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report.
Acquired lipodystrophy associated with immune checkpoint inhibitors.
Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review.
Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report.
The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
Pseudoprogression of Metastatic Melanoma to the Orbit With Pembrolizumab.
KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer.
Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report.
Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan.
Clinical and molecular insights into BCG immunotherapy for melanoma.
Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer.
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer.
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
T-cell lymphoma secondary to checkpoint inhibitor therapy.
i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism.
Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report.
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
An unusual digestive complication under anti-PD-1 (pembrolizumab).
The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.
VUS-type alteration in POLD1 and microsatellite instability in a metastatic luminal B breast cancer patient.
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer.
An Usual Presentation of Pneumocystis jirovecii Pneumonia in a Woman Treated With Immune Checkpoint Inhibitor.
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood.
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.
Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer.
Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients.
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors.
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution.
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
Novel treatments for anaplastic thyroid carcinoma.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab.
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block.
Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx.
Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report.
Lenvatinib in Management of Solid Tumors.
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Pembrolizumab-related pancreatitis with elevation of pancreatic tumour markers.
Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials.
Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Severe terminal ileitis induced by single-agent nivolumab administered every four weeks.
Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Reaserch Advance on Treatment Strategies for Relapsed/Refractory Hodgkin's Lymphoma--Review.
Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response.
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Biomarkers for immunotherapy response in head and neck cancer.
The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer.
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report.
Risk-adapted therapy for metastatic renal cell carcinoma.
Talimogene Laherparepvec plus Pembrolizumab Is Effective in Sarcomas.
Tonsillar carcinoma as a rare cause of cardiac metastases.
Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
SEOM clinical guideline for treatment of kidney cancer (2019).
"Cancer immunotherapy experience in the Integral Oncology Centre ""Diana Laura Riojas de Colosio"", Médica Sur Hospital."
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
Genetic Testing in Prostate Cancer.
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Mediastinal metastatic melanoma: an unusual case presentation of recurrent melanoma.
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Management of immune checkpoint inhibitor-related adverse events: A review of case reports.
Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
PD-1/PD-L1-dependent immune response in colorectal cancer.
Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Molecular therapies for HCC: Looking outside the box.
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life.
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.
B cells are associated with survival and immunotherapy response in sarcoma.
Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review.
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.
Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors.
Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab.
Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.
Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold.
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.
Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
PD-L1 assessment in urothelial carcinoma: a practical approach.
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study.
Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Checkpoint Inhibitor-Induced Colitis.
Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer.
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma.
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
Microsatellite instability in Japanese female patients with triple-negative breast cancer.
Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Topography, morphology, and etiology of lymphocytic gastritis: a single institution experience.
Preferences of Canadian patients and physicians for adjuvant treatments for melanoma.
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor.
Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.
Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma.
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab.
Structure and Optimization of Checkpoint Inhibitors.
Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug.
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.
Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients.
New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation.
Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
A case of myasthenia gravis developed during pembrolizumab administration, suggesting an excitation-contraction connection disorder.
Esophageal carcinoma: Towards targeted therapies.
Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.
Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies.
Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab.
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.
Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.
Optimizing immunotherapy for gynecologic cancers.
Medical treatment of advanced cutaneous squamous-cell carcinoma.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma.
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Investigation of the Ototoxic Effect of Pembrolizumab Using a Rat Model.
Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report.
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Merkel-cell carcinoma.
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date.
Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H).
Targeting Mutant KRAS for Immunogenic Cell Death Induction.
Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumab.
Pembrolizumab microgravity crystallization experimentation.
Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.
Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Site-agnostic biomarker-guided oncology drug development.
Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Mechanisms of immune evasion in bladder cancer.
Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis.
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
Toxic epidermal necrolysis associated with pembrolizumab.
Novel agents and immune invasion in Hodgkin lymphoma.
Advances in soft-tissue sarcoma - There are no mistakes, only lessons to learn!
Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis.
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor.
Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Systemic Treatment Options in Hepatocellular Carcinoma.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma.
Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis.
Current Standard of Care in Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Prevention, diagnostics, prognostication and therapy.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.
Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab.
The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC.
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.
Hypotension During Pembrolizumab Infusion: Case Report and Literature Review.
The Evolution of Adjuvant Therapy for Melanoma.
Systemic Treatment for Advanced Hepatocellular Carcinoma.
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma.
Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistochemical Examination.
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges.
Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.
Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa.
Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy.
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.
Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.
First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors.
Management of V600E and V600K BRAF-Mutant Melanoma.
Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy.
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review.
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies.
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies.
Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Influence of immunomodulators on urological imaging.
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting.
Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
Morphological spectrum of immune check-point inhibitor therapy-associated gastritis.
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Immunotherapy for head and neck cancer: Recent advances and future directions.
Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer.
Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Immune-related adverse events after immune checkpoints inhibitors in 2019: An update.
Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.
Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.
Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.
Preferences for Immunotherapy in Melanoma: A Systematic Review.
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
Gastric Cancer in the Era of Immune Checkpoint Blockade.
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab.
Immunotherapy-related hepatitis: real-world experience from a tertiary centre.
Emerging agents and regimens for hepatocellular carcinoma.
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
Pembrolizumab-associated autoimmune haemolytic anaemia.
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.
PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
Pembrolizumab for anaplastic thyroid cancer: a case study.
Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.
Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
Targeted and novel therapy in advanced gastric cancer.
A review of checkpoint inhibitors in the management of renal cell carcinoma.
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors.
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting.
Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report.
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.
Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer.
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.
Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.
Immune gene expression in head and neck squamous cell carcinoma patients.
Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review.
Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
Response of patients with melanoma to immune checkpoint blockade - insights gleaned from analysis of a new mathematical mechanistic model.
Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
Current targeted therapies in lymphomas.
Progress in rare central nervous system tumors.
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab.
Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Novel immune-modulating drugs for advanced head and neck cancer.
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome.
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.
Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers.
Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies.
Advancements and challenges in treating advanced gastric cancer in the West.
Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries.
Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.
The Landmark Series: Non-melanoma Skin Cancers.
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development.
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Melanoma Development: Current Knowledge on Melanoma Pathogenesis.
An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine.
Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors.
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors.
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
Ocular adverse events with immune checkpoint inhibitors.
Immune checkpoint blockade in small cell lung cancer.
Role of CXCR3 signaling in response to anti-PD-1 therapy.
Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis.
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma.
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.
Current status and prognosis of immune checkpoint inhibitors for esophageal cancer.
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
The impact of corticosteroid use during anti-PD1 treatment.
Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab.
Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data.
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Late-line treatment in metastatic gastric cancer: today and tomorrow.
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Review: Gastric cancer-Clinical aspects.
Emerging therapeutic agents for genitourinary cancers.
Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors.
Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.
Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid.
Immune checkpoint inhibition in Merkel cell carcinoma.
Updates on Merkel Cell Carcinoma.
Current Status of Gene Therapy in Hepatocellular Carcinoma.
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Immunotherapy for non-small cell lung cancer.
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Severe tracheal stenosis after first administration of pembrolizumab rescued by Dumon Y-stent in a lung cancer patient.
Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review.
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag.
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
The Changing Therapeutic Landscape of Metastatic Renal Cancer.
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.
Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.
Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence.
Advances in the treatment of gastric cancer: 2019.
Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Checkpoint inhibitor induced diabetes mellitus.
Pembrolizumab in lung cancer: current evidence and future perspectives.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence.
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events.
Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy.
Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade.
Neoadjuvant Pembrolizumab Takes on TNBC.
Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer.
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.
Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab.
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab.
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Mycobacterium bovis BCG in metastatic melanoma therapy.
Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review.
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.
Immunogenicity of pembrolizumab in patients with advanced tumors.
Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV.
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody).
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.
Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer.
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Expression of V-set immunoregulatory receptor in malignant mesothelioma.
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value.
Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.
An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab.
Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report.
Current and Future Systemic Therapies for Hepatocellular Carcinoma.
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort.
Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
Tumour flare reaction in cancer treatments: a comprehensive literature review.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic.
A case of myasthenia gravis and myositis induced by pembrolizumab.
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement.
Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
"Effectiveness and safety of ""real"" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review."
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
ISMP Adverse Drug Reactions: Pheochromocytoma Crisis Induced by Metoclopramide Baclofen Dependence Following High-Dose Therapy Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Acute Anterograde Amnestic Syndrome Induced by Fentanyl Ivermectin-Induced Toxic Epidermal Necrolysis Pembrolizumab-Induced Type 1 Diabetes.
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer.
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change.
Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma.
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib.
Implications of Immunotherapy in Hepatobiliary Tumors.
Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy.
The Three P's: Parotid, PD-L1, and Pembrolizumab.
Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience.
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Recent advances in HIV-associated Kaposi sarcoma.
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer.
Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis.
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Immune checkpoint inhibitors for hepatocellular carcinoma.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Recurrent amelanotic melanoma of nasal cavity: Biological variability and unpredictable behavior of mucosal melanoma. A case report.
Programmed Death 1 Inhibitor-Induced Hypothyroidism on the Palliative Care Unit: Case Report.
Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT.
Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report.
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Pancreatic cancer 'mismatch' in Lynch syndrome.
Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer.
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Programmed Cell Death-1 Monoclonal Antibody Therapy and Type 1 Diabetes Mellitus: A Review of the Literature.
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy.
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.
Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.
Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients.
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
American Society of Clinical Oncology (ASCO) - 55th Annual Meeting (May 31-June 4, 2019 - Chicago, Illinois, USA).
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma.
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier.
Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review.
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.
Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports.
Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review.
50 years of systemic therapy of urinary bladder cancer.
Approach to the Patient with Recurrent/Metastatic Disease.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population.
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma.
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.
Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review.
How I treat MSI cancers with advanced disease.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report.
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer.
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report.
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor.
Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators.
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer.
A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles.
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Colonic Metastasis of Lung Adenocarcinoma: A Case Report.
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.
Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships.
Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors.
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors.
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Cascade of immunologic adverse events related to pembrolizumab treatment.
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection.
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
A paradigm shift in biomarker guided oncology drug development.
Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Correction to: Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.
Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab.
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids.
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway.
Primary central nervous system lymphoma following immunotherapy for metastatic melanoma.
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Developments in Systemic Therapy for Soft Tissue and Bone Sarcomas.
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma.
Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer.
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Pembrolizumab-Induced Thyroiditis.
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience.
Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.
Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.
Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer.
Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
Drug repurposing to overcome resistance to various therapies for colorectal cancer.
Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.
Peripheral memory and naïve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response.
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Acquired generalized lipodystrophy under immune checkpoint inhibition.
Current recommendations and recent progress in endometrial cancer.
Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti-PD-1 Therapy.
Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
A Rare Case of Stage IV Basaloid Squamous Cell Cancer with Intrapulmonary and Brain Metastases.
Nivolumab plus ipilimumab in non-small-cell lung cancer.
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Management of immune related adverse events induced by immune checkpoint inhibition.
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Molecular tumor board prostate cancer.
Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Emerging therapies for small cell lung cancer.
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.
Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma.
The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer.
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Management of metastatic bladder cancer.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies.
Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report.
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature.
Poorly differentiated adenocarcinoma of an unknown primary with a thyroid tumour and an aggressive course: thyroid or lung carcinoma?
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Recent trends in the treatment of unresectable stage III non-small-cell lung cancer.
Vision loss with pembrolizumab treatment: A report of two cases.
Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient.
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
Current advances in Hodgkin's lymphoma.
Managing cardiotoxicity associated with immune checkpoint inhibitors.
What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.
Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
Combined Checkpoint Inhibition and Chemotherapy: New Era of  1st-Line Treatment for Non-Small-Cell Lung Cancer.
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Immunotherapy in first-line for advanced non-small cell lung cancer: <br>a cost-effective choice?
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases.
Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials.
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review.
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy.
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.
Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer.
Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis.
Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.
Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
Entinostat Helps Thwart Immunotherapy Resistance.
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs.
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Immunotherapy of Melanoma: Facts and Hopes.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.
Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma.
Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update.
Immunological Agents Used in Cancer Treatment.
Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Born to Kill: NK Cells Go to War against Cancer.
Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Enlarged mediastinal lymph nodes of a patient with malignant melanoma stage IV under pembrolizumab treatment.
Controversies in the Treatment of Classical Hodgkin Lymphoma.
Immunotherapy in colorectal cancer: rationale, challenges and potential.
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Seed and soil? - Pharyngeal Merkel cell carcinoma after radiotherapy for laryngeal squamous cell carcinoma.
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
New and Novel Therapies for Gynecologic Cancers.
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma.
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
"A ""Crazy Paving"" Pattern on CT Scan in a Patient Treated with Pembrolizumab."
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Inflammatory myopathy associated with PD-1 inhibitors.
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Risk of Pneumonitis with the Use of Different Immune Checkpoint Inhibitors in a Mexican Population.
Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work.
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab.
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy.
Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.
The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Targeting advanced urothelial carcinoma-developing strategies.
The extent of surgery for stage III melanoma: how much is appropriate?
Immunotherapy in Bladder Cancer.
Immunotherapy in Nonmelanoma Skin Cancer.
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer.
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Hematologic Complications of Immune Checkpoint Inhibitors.
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management.
PD-1/PD-L1 Inhibitors for Non-Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management.
Multiple keratin granulomata: A potential histologic clue to cutaneous squamous cell carcinoma responding to programmed cell death protein 1 inhibitor therapy.
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
Immunotherapy for advanced lung cancer combined with surgery for mediastinal myxofibrosarcoma: a case report.
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.
Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.
Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects.
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
Multiple sclerosis outcomes after cancer immunotherapy.
Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy.
Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome.
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Checkpoint Inhibitor-TKI Combos Effective in RCC.
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
"Curative effect assessment of immunotherapy for non-small cell lung cancer: The ""blind area"" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)."
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
PD-1/PD-L1 Inhibitors in Cervical Cancer.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy.
Characteristics of mismatch repair deficiency in sarcomas.
The Immune Checkpoints Inhibitors for Head and Neck Cancer.
Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition.
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors.
Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.
Use of Immune Checkpoint Inhibitors in Mesothelioma.
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia.
Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Renal toxicities associated with Pembrolizumab.
Pembrolizumab-related renal toxicities: diagnosis first, treatment later.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade.
Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer.
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
A mismatch repair-deficient and HPV-negative anorectal squamous cell carcinoma.
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia.
Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
Ring-shaped lesions on a lung scan.
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis.
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Immune therapy of melanoma: Overview of therapeutic vaccines.
A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer.
FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.
Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.
New perspectives in Merkel cell carcinoma.
Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea.
Patterns of immunotherapy use and management of toxicities in regional and tertiary settings.
Treatment sequencing in metastatic colorectal cancer.
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.
The promising role of monoclonal antibodies for gastric cancer treatment.
PD-1 inhibitor induced alopecia areata.
High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Targeted Therapy and Immunotherapy for Melanoma in Japan.
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma.
Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation.
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer.
Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience.
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Pembrolizumab resolves adult ashy dermatosis developing in patients with squamous cell carcinoma of the lung.
Advanced stage melanoma therapies: Detailing the present and exploring the future.
Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Tuberculosis following PD-1 blockade for cancer immunotherapy.
Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors.
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer.
Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Isolated Abducens Nerve Palsy Following Pembrolizumab.
Specific immunotherapies in the treatment of cancers.
Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor.
The role of immunotherapy in small cell lung cancer.
New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer.
Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.
Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases.
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.
Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada.
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.
Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors.
Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study.
Pembrolizumab for non-small cell lung cancer with central nervous system metastases: A two-case report.
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer.
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
ASCO 2018: highlights of urothelial cancer and prostate cancer.
Novel Immunotherapeutic Approaches in Head and Neck Cancer.
Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.
What's new in oncodermatology?
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
Immunotherapy Advances in Urothelial Carcinoma.
Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.
Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.
Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report.
An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function.
Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan.
Immune Checkpoint Inhibitors-Induced Hepatitis.
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma.
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies.
The value of immunotherapy in head and neck cancer.
Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Systemic treatments for thymoma and thymic carcinoma: A systematic review.
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.
Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
The clinical utility of tumor mutational burden in non-small cell lung cancer.
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents.
Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Where does PD-1 blockade fit in HL therapy?
FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis.
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.
Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy.
The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.
An isolated der(1;21)(q10;q10) translocation in a patient with myelodysplastic syndrome: a case report.
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation.
Prime time for immunotherapy in advanced urothelial cancer.
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
Implementing value assessment in oncology practice: A single-center experience.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Moving things forward in Hodgkin lymphoma.
Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs.
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
Predictors of immunotherapy-induced immune-related adverse events.
JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.
Combatting mucosal melanoma: recent advances and future perspectives.
Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.
Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Integrins as A New Target for Cancer Treatment.
A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery.
Diagnosis and Treatment of MSI-H Cancer in the Urological Malignancy.
Immunotherapy for Head and Neck Cancer.
Laparoscopic intragastric resection of melanoma cardial lesion.
Predicting Treatment Response Based on RNA Expression in Large Datasets.
Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation.
The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.
Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Review of Immune Therapies Targeting Ovarian Cancer.
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis.
The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status.
Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report.
Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer.
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.
Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?
A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B.
Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.
Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Pembro Ups Survival in PD-L1-positive HNSCC.
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
The treatment of older Hodgkin lymphoma patients.
Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Factors associated with immunotherapy selection in patients with advanced melanoma.
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Efficient Development of Stable Recombinant Chinese Hamster Ovary (rCHO) Cell Lines to Produce Antibodies by Using Dimethyl Sulfoxide (DMSO) in Electroporation.
A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability.
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Combining Biomarkers for Immunotherapy.
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
A Novel Online Four-Dimensional SEC×SEC-IM×MS Methodology for Characterization of Monoclonal Antibody Size Variants.
Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.
Cross-cancer Prediction: A Novel Machine Learning Approach to Discover Molecular Targets for Development of Treatments for Multiple Cancers.
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis.
Diabetic ketoacidosis induced by a single dose of pembrolizumab.
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
PD-1 Blockade in Early-Stage Lung Cancer.
Cancer immunotherapy-associated hypophysitis.
Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Successful pembrolizumab therapy in metastasized adenosquamous carcinoma of the colon.
Mode of action, new targets and potential biomarkers in modern immunotherapy.
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection.
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.
Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety.
Immunotherapy for the treatment of prostate cancer-a comeback?
Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer.
Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
Complete Tumor Response of Tracheal Squamous Cell Carcinoma After Treatment With Pembrolizumab.
Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI).
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.
Conjunctival Metastasis of a Cutaneous Melanoma.
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.
Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Immunotherapeutic Approaches to Head and Neck Cancer.
Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma.
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.
Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Updates and novel treatments in urothelial carcinoma.
Nivolumab for the treatment of hepatocellular carcinoma.
Advances in the treatment of gastric cancer.
Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.
Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy.
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
Bilateral anterior uveitis after immunotherapy for malignant melanoma.
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Chronic lymphocytic leukemia treatment algorithm 2018.
A case of solitary paraaortic lymph node recurrence of lung squamous cell carcinoma after resection.
Pembrolizumab for the treatment of gastric cancer.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab.
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Polymyalgia rheumatica due to pembrolizumab therapy.
Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
Uterine leiomyosarcoma: A review of the literature and update on management options.
Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Thyroid disorders induced by checkpoint inhibitors.
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.
Cost of Oncology Drugs in the Middle-Eastern Country of Lebanon: An Update (2014-2016).
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Immunotherapy for Merkel Cell Carcinoma.
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression.
A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors.
Challenging Cases: Management of Immune-Related Toxicity.
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Moving From Mutation to Actionability.
Combination Immunotherapy Development in Melanoma.
New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?
Use of checkpoint inhibitors in liver transplant recipients.
Recent advances in the management of gastric adenocarcinoma patients.
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases.
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.
The unique biology and treatment of primary mediastinal B-cell lymphoma.
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
Immune Checkpoint Inhibition in Head and Neck Cancer.
The Option Value of Innovative Treatments for Metastatic Melanoma.
Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic.
Pembrolizumab for the first-line treatment of non-small cell lung cancer.
Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study.
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency.
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.
Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
Acceptability and effectiveness of immunotherapy in patients with melanoma.
Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK.
Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma.
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Immune checkpoint inhibitors for urothelial carcinoma.
Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.
Selecting immuno-oncology-based drug combinations - what should we be considering?
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy.
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Immunotherapy in melanoma.
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.
Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Tissue and Blood Biomarkers in Lung Cancer: A Review.
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Design considerations for early-phase clinical trials of immune-oncology agents.
Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab.
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Malignant Melanoma Metastasizes to Colonic Polyp.
Harnessing the Immune System in Pancreatic Cancer.
Abscopal effect of radiation on lymph node metastasis in esophageal carcinoma: A case report and literature review.
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
Management of Brain Metastases in the New Era of Checkpoint Inhibition.
Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors.
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity.
Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
Skin cancer management-updates on Merkel cell carcinoma.
Review of checkpoint immunotherapy for the management of non-small cell lung cancer.
The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?
Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.
Immune check-point in cervical cancer.
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access.
Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.
Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
Immune Checkpoint Inhibitor Toxicity.
Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.
Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE.
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Inherited gynaecological cancers.
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper.
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.
Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
Dynamic testing of stimulative and suppressive biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.
Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review.
Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?
Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Cardiorenal complications of immune checkpoint inhibitors.
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Sick sinus syndrome associated with anti-programmed cell death-1.
Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.
Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.
A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.
Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.
Management of melanoma in patients with chronic lymphocytic leukemia.
Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Metastatic Merkel-cell carcinoma: the dawn of a new era.
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade.
Recent developments with immunotherapy for hepatocellular carcinoma.
Immunotherapy-based combinations: an update.
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients.
Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report.
Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis.
What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.
Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer.
Pembrolizumab OK'd for Cervical Cancer.
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients.
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Primary Solitary Intracranial Malignant Melanoma: A Systematic Review of Literature.
Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?
Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.
It is finally time for adjuvant therapy in melanoma.
Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Anti-PD-1 Therapy-Associated Perforating Colitis.
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
A review of guidelines for lung cancer.
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.
Immunotherapy-induced pneumonitis: cases report.
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives.
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
"Developments in urologic oncology ""OncoForum"": The best of 2017."
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Immune Checkpoint Blockade across the Cancer Care Continuum.
Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.
Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma.
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report.
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
A case of severe Pembrolizumab-induced neutropenia.
Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.
Mechanisms and Therapy for Cancer Metastasis to the Brain.
Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Checkpoint blockade in esophagogastric cancer.
Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
Pembrolizumab Monotherapy for NSCLC Extends Survival.
Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers.
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Managing adverse effects of immunotherapy.
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.
CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations.
Endometrial cancer: Molecular markers and management of advanced stage disease.
MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Cancer immunotherapy.
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
Cutaneous toxicities of new treatments for melanoma.
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
Advances in antibody therapeutics targeting small-cell lung cancer.
Managing the Adverse Effects Related to Immune Checkpoint Inhibitors.
Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data.
The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma.
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
Pembrolizumab-induced acute thrombosis: A case report.
Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.
Precision medicine becomes reality-tumor type-agnostic therapy.
Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.
From the Valley of Death to the Crossroads of Opportunity: A Discussion of Evolving Benefit/Risk Evaluation Standards.
Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.
Immune checkpoint inhibitors in gastrointestinal malignancies.
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Promising New Agents for Colorectal Cancer.
Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab: A case report.
Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Checkpoint inhibition in lymphoma.
Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab.
Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Systemic Therapies for Advanced Squamous Cell Anal Cancer.
Check point inhibitors a new era in renal cell carcinoma treatment.
Medication use evaluation of programmed death-1 inhibitors in a veteran population.
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury.
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab.
Checkpoint Inhibitors in the Treatment of Breast Cancer.
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
New Therapies in Head and Neck Cancer.
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective.
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Checkpoint Inhibitor Immune Therapy: Systemic Indications and Ophthalmic Side Effects.
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
Combo Therapy for Lung Cancer Extends Survival.
Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects.
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
PD-L1 expression testing in non-small cell lung cancer.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Adjuvant Therapy for Melanoma Prolongs RFS.
Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
Advanced bladder cancer : From chemo- to immunotherapy.
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Immunotherapy of melanoma.
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.
Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS.
Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.
Clinical assessment of immune-related adverse events.
Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases.
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Hodgkin Lymphoma - Update 2018.
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.
Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
Immune checkpoint inhibitors in small cell lung cancer.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
Immune checkpoint inhibition in metastatic urothelial carcinoma.
Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports.
Inhaled Immunotherapy Administration for Lung Cancer; Efficient? Certainly Possible.
Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists.
Melanoma and Immune Checkpoint Inhibitors.
Mucosal Melanoma: a Literature Review.
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Updates on immunotherapy for colorectal cancer.
A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Nivolumab in squamous cell carcinoma of the head and neck.
Recent advances in medical therapy for metastatic urothelial cancer.
The emerging role of immunotherapy in advanced urothelial cancers.
Current status and perspectives in immunotherapy for metastatic melanoma.
Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?
Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.
Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with Pembrolizumab.
Update in Systemic and Targeted Therapies in Gastrointestinal Oncology.
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.
Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors.
Current and future therapeutic approaches for the treatment of small cell lung cancer.
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.
Managing seminomatous and nonseminomatous germ cell tumors.
Targeting immune checkpoints in non small cell lung cancer.
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets.
Cancer immunotherapy in patients with brain metastases.
Durvalumab for the treatment of urothelial carcinoma.
Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.
Biopsy-Proven Metastatic Merkel Cell Carcinoma to the Orbit: Case Report and Review of Literature.
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
Melanoma Immunotherapy in the Elderly.
Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
New developments in the management of head and neck cancer - impact of pembrolizumab.
Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression.
The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages.
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy.
Diabetes and Blood Glucose Disorders Under Anti-PD1.
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma.
Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.
Major clinical research advances in gynecologic cancer in 2017.
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma.
Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?
Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis.
Immune Checkpoint Inhibition in Hodgkin Lymphoma.
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Perspectives in Head and Neck Medical Oncology.
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Immunotherapy for recurrent/metastatic head and neck cancer.
Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
Emerging immune targets for the treatment of multiple myeloma.
Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor.
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Immune checkpoint inhibitors for metastatic bladder cancer.
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression.
Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient.
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma.
Anorectal Malignant Melanoma Is a Very Rare Disease and Has a Poor Prognosis.
A Case of Duodenum Dissemination after Surgery for Transverse Colon Carcinoma Which Was Unresponsive to Chemotherapy, but Immunotherapy Was Significantly Effective.
Acute liver failure caused by Pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.
Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.
Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders.
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.
Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
New drugs and new toxicities: pembrolizumab-induced myocarditis.
SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
The NCI-MATCH trial and precision medicine in gynecologic cancers.
Cancer immunology and melanoma immunotherapy.
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
The differences in the assessments of side effects at an oncology outpatient clinic.
Hypermutated Tumors and Immune Checkpoint Inhibition.
Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance.
Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck.
A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma.
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma.
Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.
Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.
Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.
Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.
Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer.
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Pembrolizumab for the treatment of melanoma: updates and perspectives.
Combination strategies in melanoma therapy.
Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma.
Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
Pembrolizumab for the treatment of bladder cancer.
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Tumor Immuno-Environment in Cancer Progression and Therapy.
Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma.
Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.
Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review.
Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Immunotherapy in triple-negative breast cancer.
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy.
Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.
Current and future immunotherapies for thyroid cancer.
Treatment of advanced melanoma - A changing landscape.
Immunotherapy of Colorectal and Anal Carcinoma.
Immunotherapy of Renal Cell Carcinoma.
Combined Regimens in Immunotherapy.
Advances in Immunotherapy of Malignant Melanoma.
Immunotherapy in the Treatment of Lung Cancer.
Immunotherapy for Bladder Cancer.
Anti-PD-1 Therapy OK for Most with HIV.
Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
Role for Immune Therapy in Advanced Breast Cancer.
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.
Activated HGF-c-Met Axis in Head and Neck Cancer.
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Neoadjuvant systemic therapy for regionally advanced melanoma.
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Two cases of granuloma annulare under anti-PD1 therapy.
Pembrolizumab in the treatment of advanced urothelial cancer.
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
New therapies for advanced, recurrent, and metastatic endometrial cancers.
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Hodgkin lymphoma: A review and update on recent progress.
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Immunotherapy in head and neck cancer: evidence and perspectives.
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.
Evolution of early phase clinical trials in oncology.
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy.
Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
Biomarkers for immunotherapy in bladder cancer: a moving target.
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
Trial watch: Immune checkpoint blockers for cancer therapy.
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis.
Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology.
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Chemotherapy for Oral Cancer.
Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.
Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.
Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.
The FDA Oncology Center of Excellence and precision medicine.
Cardiotoxicity of immune checkpoint inhibitors.
Anti-PD1/PDL1 induced psoriasis.
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Update of systemic immunotherapy for advanced urothelial carcinoma.
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
Regulation of PD-L1 by MicroRNA in Mismatch Repair Deficient-Colorectal Cancer.
Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Monoclonal Antibodies for the Treatment of Cancer.
A Reflection of the New Wave of Immunotherapy on the Clinical Study of  Chinese Lung Cancer Immunotherapy.
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report.
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials.
Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
"Perspectives in immunotherapy: meeting report from the ""Immunotherapy Bridge"", Napoli, November 30th 2016."
Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies.
Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Unusual case of immune-related colitis.
Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.
Avelumab and other recent advances in Merkel cell carcinoma.
Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor.
Emerging Therapeutic Strategies in Breast Cancer.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review.
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
The role of novel immunotherapies in non-Hodgkin lymphoma.
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry hyphenation.
Endocrinopathies with use of cancer immunotherapies.
Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.
The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer.
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
PD-1 checkpoint inhibition: Toxicities and management.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis.
Development of immune checkpoint inhibitors.
Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade.
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
"Immunotherapy ""Shock"" a case series of PD-L1 100% and pembrolizumab first-line treatment."
The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report.
Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Checkpoint inhibitors: a cutting edge in oncology.
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.
The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Breast Cancer Immunotherapy: Facts and Hopes.
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Pembrolizumab reactivates pulmonary granulomatosis.
Cost analysis of adverse events associated with non-small cell lung cancer management in France.
Targeting Immune System Alterations in Hodgkin Lymphoma.
Hypothyroid ataxia complicating monoclonal antibody therapy.
Why First-Line Nivolumab Is No Better than Chemo.
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
The importance for immunoregulation for long-term cancer control.
Angiogenesis inhibitors in early development for gastric cancer.
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Epacadostat Shows Value in Two SCCHN Trials.
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.
Immunotherapy: Who Is Eligible?
Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Pembrolizumab-Induced Pancytopenia: A Case Report.
Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
PD-1 Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events .
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results.
Malignant melanoma : Current status.
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy.
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
The new paradigm of systemic therapies for metastatic melanoma.
Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
MEDI 4736 (durvalumab) in non-small cell lung cancer.
Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.
An immunogenic personal neoantigen vaccine for patients with melanoma.
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Keytruda Crosses First-Line Finish Line First.
The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study.
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
Immunotherapy and non-small cell lung cancer : a (r)evolution.
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Dramatic response of metaplastic breast cancer to chemo-immunotherapy.
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
Do checkpoint inhibitors rely on gut microbiota to fight cancer?
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.
Immunotherapy in urothelial carcinoma from a pathologist's perspective.
Acute exudative paraneoplastic polymorphous vitelliform maculopathy during Vemrafenib and Pembrolizumab treatment for metastatic melanoma.
Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma.
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
Immune-related adverse events by immune checkpoint inhibitors.
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Scleroderma Induced by Pembrolizumab: A Case Series.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
The role of immunooncology in the treatment of urothelial cancer.
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Biology and evolution of poorly differentiated neuroendocrine tumors.
Immunotherapy for lung cancer.
The role of immunotherapy in the modern treatment of urothelial carcinoma.
Advances in immunotherapy for metastatic melanoma.
First Tissue-Agnostic Drug Approval Issued.
Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.
Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
Microwave Ablation and Immune Activation in the Treatment of Recurrent Colorectal Lung Metastases: A Case Report.
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.
Three Drugs Approved for Urothelial Carcinoma by FDA.
Interaction of molecular alterations with immune response in melanoma.
Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Melanoma: tumor microenvironment and new treatments.
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Immune checkpoint blockade for hematologic malignancies: a review.
Current state of immunotherapy for non-small cell lung cancer.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Hallmarks of response to immune checkpoint blockade.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Evaluation of dosing strategy for pembrolizumab for oncology indications.
Immunotherapies for Lung Cancer.
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Checkpoint inhibition and melanoma: Considerations in treating the older adult.
The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
European Association of Urology - 32nd Annual Congress (March 24-28, 2017 - London, UK).
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis.
Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Immunotherapy of patients with metastatic melanoma.
Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Locoregional and systemic therapy for hepatocellular carcinoma.
Immunotherapy: Activation of a system not a pathway.
Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors.
Immunotherapy in advanced melanoma: a network meta-analysis.
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
Current studies of immunotherapy in head and neck cancer.
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series.
Pattern recognition receptors: immune targets to enhance cancer immunotherapy.
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.
Immunotherapy in genitourinary malignancies.
The next generation of immunotherapy: keeping lung cancer in check.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone.
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Update on Chemotherapy-Induced Peripheral Neuropathy.
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Adjuvant Therapy for Melanoma.
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Pembrolizumab in recurrent advanced cervical squamous carcinoma.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Understanding current therapies in metastatic melanoma.
New paradigms and metaphors in cutaneous melanoma treatment.
Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.
Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma.
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.
Immunotherapy for colorectal cancer: where are we heading?
Hypermutations in gliomas: a potential immunotherapy target.
Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy.
Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
Pembrolizumab Approved for Hodgkin Lymphoma.
Immunotherapy for Esophageal Squamous Cell Carcinoma.
Immunotherapy for the treatment of Hodgkin lymphoma.
Could knee inflammatory synovitis be induced by pembrolizumab?
Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma.
PD-1/PD-L1 Pathway in Breast Cancer.
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Pembrolizumab for the treatment of non-small cell lung cancer.
"Nuclear IRF-1 expression as a mechanism to assess ""Capability"" to express PD-L1 and response to PD-1 therapy in metastatic melanoma."
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
Pembrolizumab use for the treatment of advanced melanoma.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
News from the melanoma sessions of the European Cancer Congress 2017.
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Management of Toxicities of Immune Checkpoint Inhibitors.
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Immunotherapy Beats Chemo for Bladder Cancer.
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
New developments in the biology and the treatment of metastatic Merkel cell carcinoma.
Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
The safety of second-line treatment options for non-small cell lung cancer.
The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Comparing available criteria for measuring brain metastasis response to immunotherapy.
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Role of pembrolizumab in the treatment of non-small cell lung cancer (NSCLC).
Drug therapy of lymphomas.
Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.
Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Immunotherapy for the treatment of multiple myeloma.
Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab.
Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease.
Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.
Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Adverse events of immune checkpoint inhibitors.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
First-line treatment of metastatic melanoma: role of nivolumab.
Immunotherapy in malignant melanoma: recent approaches and new perspectives.
Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events.
Immune checkpoint inhibitors in challenging populations.
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives.
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
A rapid response to pembrolizumab in a patient with metastatic melanoma.
The expanding role of immunotherapy.
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer.
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
New Therapeutic Strategies for Triple-Negative Breast Cancer.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.
Cutaneous adverse effects of the immune checkpoint inhibitors.
Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Checkpoint inhibition for advanced mucosal melanoma.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Chemotherapy for recurrent/metastatic head and neck cancers.
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers.
Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
Pembrolizumab-induced myasthenia gravis: A fatal case report.
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.
Primary Oral Melanoma - A Non-Surgical Approach to Treatment via Immunotherapy.
Treatment of lung cancer using immune checkpoint inhibitors.
Anti-PD-1 antibody and anti-PD-Li antibody -from basic and clinic-.
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report.
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.
Oncology pharma costs to exceed $150 billion by 2020.
Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma.
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.
Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer.
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma.
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.
Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician.
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports.
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.
A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Potential role of immunotherapy in advanced non-small-cell lung cancer.
Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases.
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Renal effects of immune checkpoint inhibitors.
Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab.
Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.
PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.
Responses to immune checkpoint inhibitors in nonagenarians.
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Commentary on Pharmacometrics for Immunotherapy.
Nivolumab in second-line treatment of squamous non-small cell lung cancer.
Novel treatment concepts in Hodgkin lymphoma.
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Resistance to PD1/PDL1 checkpoint inhibition.
Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.
First Anti-PD-L1 Drug Approved for NSCLC.
Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.
Immunotherapy in Lung Cancer.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Recent Advances in Immunotherapy in Metastatic NSCLC.
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report.
Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review.
Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
The emerging role of immune checkpoint inhibition in malignant lymphoma.
Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.
"Using Model-Based ""Learn and Confirm"" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial."
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
Hyponatraemia secondary to nivolumab-induced primary adrenal failure.
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy.
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis.
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Acute interstitial nephritis related to immune checkpoint inhibitors.
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases.
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?
Blood Assay Predicts Response to Pembrolizumab.
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
PD-1, CTLA-4 Point to Drug Response.
Durable Responses Achieved with AM0010.
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Dendritic cell and cancer immune checkpoint.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
The evolution of the treatment of advanced NSCLC.
A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
Immunotherapy in melanoma: Recent advances and future directions.
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
Trial Watch: Immunotherapy plus radiation therapy for oncological indications.
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients.
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group.
The safety of anti PD-1 therapeutics for the treatment of melanoma.
Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer.
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
Cancer immunotherapy in patients with preexisting autoimmune disorders.
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin.
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
Chemotherapy for advanced gastric cancer: future perspective in Japan.
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Immunotherapy for Gastroesophageal Cancer.
Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis.
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Cutaneous Complications of Targeted Melanoma Therapy.
Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma.
Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
Intralesional and systemic immunotherapy for metastatic melanoma.
Pembrolizumab for the treatment of advanced melanoma.
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report.
Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Immune checkpoint blockade in lung cancer.
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.
Toxicity management of immunotherapy for patients with metastatic melanoma.
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.
Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer.
Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations.
Cytotoxic and targeted therapy for hereditary cancers.
Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Immune checkpoint antibodies increase survival in patients with metastatic melanoma.
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.
Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab.
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Subsidised access to new melanoma drugs: in need of further innovation?
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.
Sequencing of New and Old Therapies for Metastatic Melanoma.
Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Pembrolizumab administration associated with posterior uveitis.
The safety and efficacy of Nivolumab in advanced (metastatic) non-small cell lung cancer.
How Melanoma Resists PD-1 Blockade.
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma.
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.
Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
(Neo)adjuvant systemic therapy for melanoma.
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab.
Immunotherapy for head and neck squamous cell carcinoma.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
PD-1/PD-L1 blockade in renal cell cancer.
Novel melanoma therapies and their side effects.
Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Ipilimumab in melanoma.
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Pembrolizumab (Keytruda).
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.
A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody.
The current status of checkpoint inhibitors in metastatic bladder cancer.
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Immunotherapy advances in uro-genital malignancies.
Cancer immunotherapy: Rational and recent breakthroughs.
Enhancing PD-1 Blockade in Solid Tumors.
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Blocking PD-1 in Tumors with Faulty DNA Repair.
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis.
Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades.
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.
Pulmonary sarcoid-like granulomatosis induced by nivolumab.
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
Merkel Cell Carcinoma Therapeutic Update.
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.
A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.
Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition.
Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.
Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma.
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Intralesional treatment for advanced melanoma: what's on the horizon?
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies.
Targeting PD-L1 for non-small-cell lung cancer.
PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab.
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
Emerging antibodies for the treatment of multiple myeloma.
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
The Role of Intralesional Therapies in Melanoma.
Choroidal Metastases From Cutaneous Melanoma.
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Pembrolizumab in classical Hodgkin's lymphoma.
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors.
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Immune-mediated respiratory adverse events of checkpoint inhibitors.
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
Endocrinological side-effects of immune checkpoint inhibitors.
PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases.
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Renaissance of immuno-oncology for urological tumors : Current status.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents.
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy.
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.
Programmed death 1 immune checkpoint inhibitors.
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.
Immune checkpoint inhibitors in lung cancer: past, present and future.
Clinical utility of nivolumab in the treatment of advanced melanoma.
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.
Limbic encephalitis following immunotherapy against metastatic malignant melanoma.
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.
Anti-PD1-induced collagenous colitis in a melanoma patient.
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.
New Translational Research in the Medical Management of Orbital Melanoma.
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.
Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab.
Immunotherapy opportunities in breast cancer.
Recent treatment advances in Hodgkin lymphoma: a concise review.
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.
Immunotherapy for small-cell lung cancer: emerging evidence.
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Management of toxicities of immune checkpoint inhibitors.
Immune checkpoint‑targeted cancer immunotherapies.
Immune checkpoint therapy for non-small-cell lung cancer: an update.
Advances in immunotherapy for melanoma.
The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.
High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma.
Pembrolizumab: A Review in Advanced Melanoma.
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.
Progression of immunotherapy in gastric cancer.
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
Current status of immunotherapy.
Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
Treatment of melanoma brain metastases.
Shedding light on the molecular determinants of response to anti-PD-1 therapy.
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
PD-1 Blockade Expands Intratumoral Memory T Cells.
Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency.
Colorectal clinical trials: what is on the horizon?
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells.
Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Modern methods of immunotherapy for metastatic melanoma.
Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to Programmed Cell Death Protein 1 Inhibitor Therapy.
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Immunotherapy in Tumors.
Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma.
Clinical management of HIV-associated hematologic malignancies.
Therapeutic Effect and Tolerance of Ipilimumam in Metastatic Malignant Melanoma in Children -  a Case Report.
Side effects of Modern Immunotherapy and How to Solve Them in the Clinics.
Single versus combination immunotherapy drug treatment in melanoma.
Furthering benefit/risk ratio and cost effectiveness of anticancer drugs.
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Solitary metastasis from melanoma causing bowel perforation.
Immunotherapy in lung cancer: checkpoint inhibitors.
Systemic therapy of metastatic melanoma.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Checkpoint Blockade for the Treatment of Advanced Melanoma.
Adjuvant Therapy of Melanoma.
Practical Approaches to Immunotherapy in the Clinic.
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Pembrolizumab for the treatment of PD-L1  positive advanced or metastatic non-small cell  lung cancer.
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant.
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Checkpoint inhibitors in Hodgkin's lymphoma.
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
Current and Future Therapies for Advanced Gastric Cancer.
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Targeting immune checkpoints in melanoma: an update.
Pembrolizumab in the management of metastatic melanoma.
Mutational profiling of colorectal cancers with microsatellite instability.
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Immune checkpoints and immunotherapy for colorectal cancer.
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
Advances in immunotherapy for treatment of lung cancer.
Immune checkpoint inhibitors: a new frontier in bladder cancer.
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Intellectual property issues of immune checkpoint inhibitors.
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.
Blinatumomab and Pembrolizumab.
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
PD-1 and PD-L1 blockade in gastrointestinal malignancies.
New developments in the management of advanced melanoma - role of pembrolizumab.
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Immunotherapy for Advanced Lung Cancer.
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Novel agents for the treatment of Hodgkin lymphoma.
Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.
PD-1 Blockers.
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.
Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo.
Anti program death-1/anti program death-ligand 1 in digestive cancers.
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.
Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Immune checkpoint inhibitors in melanoma.
Targeting PD-1/PD-L1 in lung cancer: current perspectives.
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.
Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.
Pembrolizumab for the treatment of melanoma.
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma.
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Spotlight on pembrolizumab in the treatment of advanced melanoma.
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
New immunotherapeutic approaches in oncology and hematology.
Successes and setbacks of early investigational drugs for melanoma.
The immunocheckpoints in modern oncology: the next 15 years.
Targeting immune checkpoints in lymphoma.
PD-1/PD-L1 inhibitors.
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology.
Expanding the Reach of Anti-PD-1 Therapy.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Managing immune checkpoint-blocking antibody side effects.
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Immune targeting in breast cancer.
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.
Anti-PD-1 therapy in melanoma.
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.
Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Safety of pembrolizumab for the treatment of melanoma.
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Pembrolizumab superior to ipilimumab in melanoma.
Pembrolizumab Shows Promise for NSCLC.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
The future of immune checkpoint therapy.
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
New clinical advances in immunotherapy for the treatment of solid tumours.
Immune checkpoint inhibition in lymphoid disease.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Immunotherapy for lung cancer: for whom the bell tolls?
Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
Systemic therapy of metastatic melanoma: on the road to cure.
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.
Combination approaches and anti-PD1 therapies: the focus of new research at ESMO and SMR.
PD-1 and PD-L1 antibodies for melanoma.
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Breaking immune tolerance in cancer.
Immune Checkpoint Blockade in Cancer Therapy.
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Immune checkpoint combinations from mouse to man.
Recent advances in targeted nanoparticles drug delivery to melanoma.
Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma.
Metastatic melanoma - a review of current and future treatment options.
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.
Antibodies to watch in 2015.
Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.
Pharmaceutical approval update.
Prospects for targeting PD-1 and PD-L1 in various tumor types.
Prognostic and predictive markers for the new immunotherapies.
Identification and management of toxicities from immune checkpoint-blocking drugs.
Pembrolizumab: first global approval.
Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.
Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
Immune checkpoint inhibitors in NSCLC.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Antibodies to watch in 2014: mid-year update.
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies.
PD-1 inhibitors raise survival in NSCLC.
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
"PD-1 inhibitor becomes ""breakthrough therapy""."
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
